Episode Details
Back to Episodes
Eli Lilly's Triple-Action Drug: A Game-Changer in Weight Loss
Published 1 day, 7 hours ago
Description
Eli Lillys Zepbound and upcoming drugs like Foundayo and retatrutide are revolutionizing the weight loss market, with retatrutides triple-action approach showing promising results in trials. This innovation could give Eli Lilly a significant edge over competitors like Novo Nordisk, potentially offering even greater weight loss than existing therapies.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/09298ecbe1982b21